Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 3, 2007, Pages 599-604

  Sun, Hsin Yun ^a   Hung, Chien Ching ^a   Lin, Pi Han ^b   Chang, Shu Fang ^b   Yang, Ching Yao ^b   Chang, Sui Yuan ^b   Chang, Shan Chwen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Antiretroviral therapy; Gene frequency; Pharmacogenetics

Indexed keywords

ABACAVIR; CARBAMAZEPINE; CLINDAMYCIN; COTRIMOXAZOLE; EFAVIRENZ; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA B57 ANTIGEN; NEVIRAPINE; PRIMAQUINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; AIDS RELATED COMPLEX; ALOPECIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CHINESE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DNA POLYMORPHISM; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG RECHALLENGE; DRUG WITHDRAWAL; DYSPNEA; EYE SWELLING; FEMALE; GASTROINTESTINAL DISEASE; GENE EXPRESSION; GENE FREQUENCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HLA TYPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NAUSEA AND VOMITING; NOCARDIOSIS; PATIENT COMPLIANCE; PHARMACOGENETICS; PNEUMONIA; POLYMERASE CHAIN REACTION; PRURITUS; RISK FACTOR; SCHOOL CHILD; SEQUENCE ANALYSIS; TAIWAN;

ADULT; ALLELES; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; FEMALE; GENE FREQUENCY; HIV INFECTIONS; HLA ANTIGENS; HLA-B ANTIGENS; HUMANS; MALE; POLYMORPHISM, GENETIC; TAIWAN; TERMINOLOGY AS TOPIC;

EID: 34548138997     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm243     Document Type: Article

References (23)

1. Hetherington S, McGuirk S, Powell G et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001; 23: 1603-14.
2. Cutrell AG, Hernandez JE, Fleming JW et al. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother 2004; 38: 2171-2.
3. Escaut L, Liotier JY, Albengres E et al. Abacavir rechallenge has to be avoided in case of hypersensitivity reaction. AIDS 1999; 13: 1419-20.
4. Walensky RP, Goldberg JH, Daily JP. Anaphylaxis after rechallenge with abacavir. AIDS 1999; 13: 999-1000.
5. Mallal S, Nolan D, Witt C et al. Association between the presence of HLA-B*5701, HLADR7 and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359: 727-32.
6. Hetherington S, Hughes AR, Mosteller M et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359: 1121-2.
7. Martin AM, Nolan D, Gaudieri S et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA 2004; 101: 4180-5.
8. Rauch A, Nolan D, Martin A et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian Human Immunodeficiency Virus Cohort. Clin Infect Dis 2006; 43: 99-102.
9. Reeves I, Churchill D, Fisher M et al. Screening for HLA-B*5701 reduces the frequency of abacavir hypersensitivity reactions. In: Program and Abstracts of the Eighth International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Francisco, CA, USA, 2006 Abstract 14.270. Antivir Ther 2006; 11: S1-192.
10. Waters L, Gritz A, Maitland D et al. HLA-B5701 testing and abacavir hypersensitivity: A single centre experience. In: Program and Abstracts of the 8th International Congress on Drug Therapy in HIV Infection, Glasgow UK, 2006. Abstract PL9.2.
11. Zucman D, de Truchis P, Majerholc C et al. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr 2007; 45: 1-3.
12. Nolan D, Gaudieri S, Mallal S. Pharmacogenetics: A practical role in predicting antiretroviral drug toxicity? J HIV Ther 2003; 8: 36-41.
13. Phillips EJ. Genetic screening to prevent abacavir hypersensitivity reaction: Are we there yet? Clin Infect Dis 2006; 43: 103-5.
14. Mosteller M, Hughes A, Warren L et al. Pharmacogenetic (PG) investigation of hypersensitivity to abacavir. In: Program and Abstracts of AIDS 2006 - XVI International AIDS Conference, Toronto, Canada, 2006. Abstract WEPE0171.
15. Cannings C, Edwards AW. Expected genotypic frequencies in a small sample: Deviation from Hardy-Weinberg equilibrium. Am J Hum Genet 1969; 21: 245-7.
16. Vargas-Alarcon G, Londono JD, Hernandez-Pacheco G et al. Heat shock protein 70 gene polymorphisms in Mexican patients with spondyloarthropathies. Ann Rheum Dis 2002; 61: 48-51.
17. Shen SW, Hu CY, Lin CY, et al. Human leukocyte antigen polymorphisms in the Taiwanese population. J Formos Med Assoc 1999; 98: 11-8.
18. Shaw CK, Chen LL, Lee A et al. Distribution of HLA gene and haplotype frequencies in Taiwan: A comparative study among Min-nan, Hakka, Aborigines and Mainland Chinese. Tissue Antigens 1999; 53: 51-64.
19. Li S, Jiao H, Yu X et al. Human leukocyte antigen class I and class II allele frequencies and HIV-1 Infection associations in a Chinese cohort. J Acquir Immune Defic Syndr 2007; 44: 121-31.
20. Hughes DA, Vilar FJ, Ward CC et al. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004; 14: 335-42.
21. Hughes AR, Mosteller M, Bansal AT et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004; 5: 203-11.
22. Sadiq ST, Pakianathan MR. Uncertainties of routine HLA B*5701 testing in black African HIV cohorts in the UK. Sex Transm Infect 2007; 83: 181-2.
23. Hughes S, Parry-Billings K, Givens N et al. PREDICT-1: A novel randomised prospective study design to determine the clinical utility of prognostic screening for HLA-B*5701 (Study CNA106030). In: Program and Abstracts of the 8th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 2006. Abstract P118.